Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma

Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible...

Descripción completa

Detalles Bibliográficos
Autores principales: Carpagnano, Giovanna Elisiana, Resta, Emanuela, Povero, Massimiliano, Pelaia, Corrado, D’Amato, Mariella, Crimi, Nunzio, Scichilone, Nicola, Scioscia, Giulia, Resta, Onofrio, Calabrese, Cecilia, Pelaia, Girolamo, Barbaro, Maria Pia Foschino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943587/
https://www.ncbi.nlm.nih.gov/pubmed/33750842
http://dx.doi.org/10.1038/s41598-021-84895-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943587/
https://www.ncbi.nlm.nih.gov/pubmed/33750842
http://dx.doi.org/10.1038/s41598-021-84895-2

Ejemplares similares